Federal approval of a "female Viagra" made headlines last year, but few women have gotten it, a news report says.

The drug, Addyi (flibanserin), won U.S. Food and Drug Administration approval in August, but only 1,000 prescriptions for the pill were filled during its first two months on the market. By comparison, about 500,000 men landed Viagra prescriptions during that drug’s first month of sales in 1998, according to the Pittsburgh Post-Gazette.

The drug is the first medication designed to target sexual dysfunction in women, but interest in it has cooled due to federal restrictions and studies that showed it provided limited success, the report quotes analysts as saying.

"Women are just smarter than the drug company thought," said Beth A. Prairie, a midlife-gynecology specialist at West Penn Hospital in Pittsburgh, told the paper. The medication has proven “very expensive and not very effective,” she added.

Viagra is marketed at men who experience erectile dysfunction, which numbers in the millions, while Addyi is approved for women with hypoactive sexual desire disorder, or HSDD, a libido-diminishing condition that affects up to 10 percent of women in the U.S., about only half of which the drug would help, its manufacturer has said. 

Also, unlike Viagra, the FDA requires pharmacies and physicians to receive special certification before supplying the drug, whose side effects can include nausea and drowsiness, the article noted.